Dr. Ori Hampel, MD

Dr. Hampel practices at Adult And Pediatric Urology Of Houston in Pasadena, Texas.

Dr. Hampel's NPI, 1144387705, was assigned on January 3, 2007. Dr. Hampel graduated from Cleveland Medical College, Homeopathic in 1992. Dr. Hampel holds Texas license J5096.

Dr. Hampel's primary practice is Adult and Pediatric Urology of Houston, at 3230 Strawberry Rd, Pasadena, TX 77504-1760. The practice phone is (713) 477-8600.

Dr. Hampel's primary practice is Adult And Pediatric Urology Of Houston in Pasadena, Texas. Dr. Hampel is also affiliated with HCA Houston Healthcare Southeast. The medical group on file is Adult and Pediatric Urology of Houston. Dmand AI also links Dr. Hampel to 5 more hospitals, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hampel practices, 8 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Hampel's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Hampel is board certified in urology by the American Board of Urology. Dmand AI has Dr. Hampel's licenses on file in 4 states: Texas, Colorado, Maryland and Pennsylvania.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney disease, kidney removal surgery and kidney stone disease among the conditions Dr. Hampel treats.

CMS data shows 3,019 Medicare services from Dr. Hampel across 23 procedure codes in 2024, for 453 Medicare patients. Medicare paid $172,051 for them.

CMS counts 453 Medicare patients who saw Dr. Hampel in 2024. The largest group is 65 to 74, with 189 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hampel's median patient age at 72, with 28% women.

In 2024, Dr. Hampel wrote 2,538 Medicare Part D claims for 934 patients. 91% of them were for generic drugs. CMS names the drug for 2,409 of them, across 33 drugs with 11 or more claims each, at $360,518 in total drug cost. In 2023, CMS named 2,974 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Hampel for performance year 2024, reported individually. Dr. Hampel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 34 procedures of prostate resection by Dr. Hampel, more than 93% of the clinicians it reports for that procedure.

Dmand AI links 4 papers to Dr. Hampel in 2024. The most frequent topics are Adenocarcinoma and Prostatic Neoplasms. Dr. Hampel has published most often in J Urol. Dr. Hampel's most frequent co-authors are Thomas Michael Wheeler, MD, Marco Marcelli, MD and Rahul K. Nath, MD.

CMS Open Payments shows 548 general payments to Dr. Hampel from 48 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 89% of the total. Astellas Pharma US Inc paid the most, $1,858.

Dr. Hampel graduated from Cleveland Medical College, Homeopathic in 1992. Dr. Hampel is a member of TMA.

Dr. Hampel is in network with 22 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.